The activation of CB2 in RA synoviocytes by CB2 agonist has been shown to block the production of pro-inflammatory mediators, inhibiting the adenylyl cyclase, thus decreasing the production of cAMP. This evidence concerns the gene CNR2 and rheumatoid arthritis.